Professor Mark Hatherill  
**Director, South African Tuberculosis Vaccine Initiative (SATVI)**  
University of Cape Town

Professor Mark Hatherill is Director and leader of the clinical research team of the South African Tuberculosis Vaccine Initiative (SATVI), a University of Cape Town research group focused on understanding risk for and protection against TB, to develop better vaccines and preventive therapies to impact the global epidemic. A University of Cape Town medical graduate, he trained as a pediatrician and critical care sub-specialist. Since 2005, SATVI has conducted 28 clinical trials of 9 novel TB vaccine candidates involving almost 6,000 participants, in addition to large epidemiological and immunological cohort studies. Prof Hatherill played a lead role in efficacy trials that tested the candidate vaccine MVA85A for prevention of TB disease in infants; BCG revaccination for prevention of *M. tuberculosis* infection in adolescents; and the candidate vaccine M72/AS01e for prevention of TB disease in adults. He is Co-PI of the Regional Prospective Observational Research in Tuberculosis (RePORT) South Africa consortium. His current work focuses on the design and implementation of clinical trials of novel TB vaccines and biomarker-targeted TB prevention.